Table 13.
Nanoparticles | Method of Preparation | Size | Zeta Potential | Dose (EC) | Experimental Model | Indication | Benefits/ Advantages |
References |
---|---|---|---|---|---|---|---|---|
TQ-loaded nanocapsule | Nanoprecipitation | 70.21 nm | –45.3 mV | 10 mg/kg TQ-loaded NCs |
Streptozotocin plus nicotinamide–induced diabetic Wistar female albino rats | Anti-diabetes |
|
[316] |
TQ-loaded phospholipid nanoconstructs | Micro-emulsification technique | 83.44 nm | −0.65 mV | 20 mg/kg | Wistar rats | Hepatoprotection |
|
[317] |
TQ-capped iron oxide nanoparticles | Co-precipitation method | 10 nm | −33.4 ± 1.5 mV | 0.05, 0.1, 0.15, 0.2, and 0.25 mg/mL |
MDA-MB-231 (epithelial, human breast cancer cell) | Chemo-Photothermal Therapy of Cancer |
|
[318] |
TQ-loaded chitosan-lecithin micelles | 50 nm to 100 nm | - | 200 µL of 20 mg/mL of TQ-PMs |
Balb/c mice | Wound healing efficacy |
|
[319] | |
TQ-loaded nanoformulation | Emulsion solvent evaporation method | 97.36 ± 2.01 nm | −17.98 ± 1.09 | 10 mg kg−1 | Albino rats | Epilepsy |
|
[320] |
TQ-loaded Chitosan nanoparticles (TQ-TPP-Cs NPs) | Bio-fabrication and statistical optimization | 391.4 ± 78.35 | 30.9 ± 3.02 mV | (141.91 mg/kg | Wistar rodents |
Depression |
|
[321] |
TQ-loaded, hyaluronic acid (HA)-conjugated Pluronic® P123 and F127 copolymer nanoparticles (HA-TQ-Nps) |
15–20 nm | -- | 1.5, 2, 3 μg/mL | Two human TNBC cell lines such as MDA-MB-231 and MDA-MB-468 | Triple-negative breast cancer |
|
[322] | |
TQ-loaded polymeric nanocapsules | nanoprecipitation technique | 217 to 231.5 nm | −36 to −39 mV | 100, 200, 300, 400 μM | Colon cancer cell lines (HT-29, HCT-116, Caco-2) | Colon cancer |
|
[323] |
TQ solid lipid nanoparticles | solvent injection methods | 20 mg/kg | Male Albino Wistar rats | Depression |
|
[64] | ||
Ethosomic TQ | Conventional method | 20 ± 1 nm | −63 ± 2 mv | Human epithelial breast cancer cell lines MCF-7 | Breast cancer |
|
[324] |